G. DavidRoodmanMD

PubMed

• Osteoclast-derived IGF1 induces RANKL production in osteocytes and contributes to pagetic lesion formation.
  Kazuaki Miyagawa, Hirofumi Tenshin, Patrick L Mulcrone, Jesus Delgado-Calle, Mark A Subler, Jolene J Windle, John M Chirgwin, G David Roodman, Noriyoshi Kurihara> ;JCI Insight. 2023 Jul 24
• 6 citations
  Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction.
  Hayley M Sabol, Tânia Amorim, Cody Ashby, David Halladay, Judith Anderson, Meloney Cregor, Megan Sweet, Intawat Nookaew, Noriyoshi Kurihara, G David Roodman, Teresita ...> ;Neoplasia. 2022 Jun 1
• 4 citations
  GFI1-Dependent Repression ofIncreases Multiple Myeloma Cell Survival.
  Daniela N Petrusca, Patrick L Mulcrone, David A Macar, Ryan T Bishop, Evgeny Berdyshev, Attaya Suvannasankha, Judith L Anderson, Quanhong Sun, Philip E Auron, Deborah ...> ;Cancers. 2022 Feb 2
• 14 citations
  Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity.
  Hayley M. Sabol, Adam J. Ferrari, Manish Adhikari, Tânia Amorim, Kevin McAndrews, Judith L. Anderson, Michele Vigolo, Rajwinder Lehal, Meloney Cregor, Sharmin Khan, Pe...> ;Cancer Research. 2021 Aug 4
• 18 citations
  The HMGB1/RAGE axis induces bone pain associated with colonization of 4T1 mouse breast cancer in bone
  Tatsuo Okui, Masahiro Hiasa, Shoji Ryumon, Kisho Ono, Yuki Kunisada, Soichiro Ibaragi, Akira Sasaki, G. David Roodman, Fletcher A. White, Toshiyuki Yoneda> ;Journal of Bone Oncology. 2021 Feb 28
• 7 citations
  Increased S1P expression in osteoclasts enhances bone formation in an animal model of Paget's disease.
  Yuki Nagata, Kazuaki Miyagawa, Yasuhisa Ohata, Daniela N. Petrusca, Gabriel M. Pagnotti, Khalid S. Mohammad, Theresa A. Guise, Jolene J. Windle, G. David Roodman, Nori...> ;Journal of Cellular Biochemistry. 2021 Apr 1
• 17 citations
  Osteocyte Vegf-a contributes to myeloma-associated angiogenesis and is regulated by Fgf23
  Patrick L. Mulcrone, Shanique K. E. Edwards, Daniela N. Petrusca, Laura S. Haneline, Jesus Delgado-Calle, G. David Roodman> ;Scientific Reports. 2020 Oct 14
• 4 citations
  Summary of the 2019 BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling
  Sarah A. Holstein, Alan Howard, David Avigan, Manisha Bhutani, Adam D. Cohen, Luciano J. Costa, Madhav V. Dhodapkar, Nicole J. Gormley, Damian J. Green, Jens Hillengas...> ;Biology of Blood and Marrow Transplantation. 2020 Jun 24
• 10 citations
  Juvenile Paget's disease from heterozygous mutation of SP7 encoding osterix (specificity protein 7, transcription factor SP7)
  Michael P. Whyte, Philippe M. Campeau, William H. McAlister, G. David Roodman, Nori Kurihara, Angela Nenninger, Shenghui Duan, Gary S. Gottesman, Vinieth N. Bijanki, H...> ;Bone. 2020 Aug 1
• 7 citations
  Osteoclast-derived IGF1 is required for pagetic lesion formation in vivo
  Kazuaki Miyagawa, Yasuhisa Ohata, Jesus Delgado-Calle, Jumpei Teramachi, Hua Zhou, David D. Dempster, Mark A. Subler, Jolene J. Windle, John M. Chirgwin, G. David Rood...> ;JCI Insight. 2020 Mar 26
• 15 citations
  Therapeutic targets in myeloma bone disease.
  Silvia Marino, Daniela N. Petrusca, G. David Roodman> ;British Journal of Pharmacology. 2021 May 1
• 21 citations
  Aplidin (plitidepsin) is a novel anti-myeloma agent with potent anti-resorptive activity mediated by direct effects on osteoclasts
  Jesus Delgado-Calle, Noriyoshi Kurihara, Emily G. Atkinson, Jessica Nelson, Kazuaki Miyagawa, Carlos M. Galmarini, G. David Roodman, Teresita Bellido> ;Oncotarget. 2019 Apr 12
• Deciphering Cancer and Bone Interactions for Therapeutic Benefits.
  G David Roodman> ;JBMR Plus. 2019 Mar 1
• 17 citations
  Epigenetic-Based Mechanisms of Osteoblast Suppression in Multiple Myeloma Bone Disease.
  Juraj Adamik, G. David Roodman, Deborah L. Galson> ;JBMR Plus. 2019 Mar 1
• 11 citations
  Growth factor independence 1 expression in myeloma cells enhances their growth, survival, and osteoclastogenesis.
  Daniela N. Petrusca, Denise Toscani, Feng-Ming Wang, Cheolkyu Park, Colin D. Crean, Judith L. Anderson, Silvia Marino, Khalid S. Mohammad, Dan Zhou, Rebecca Silbermann...> ;Journal of Hematology & Oncology. 2018 Oct 4
• 26 citations
  Osteoblast suppression in multiple myeloma bone disease.
  Juraj Adamik, Deborah L. Galson, G. David Roodman> ;Journal of Bone Oncology. 2018 Sep 15
• 33 citations
  Multiple Myeloma and Bone: The Fatal Interaction
  Silvia Marino, G. David Roodman> ;Cold Spring Harbor Perspectives in Medicine. 2018 Aug 1
• 17 citations
  XRK3F2 Inhibition of p62-ZZ Domain Signaling Rescues Myeloma-Induced GFI1-Driven Epigenetic Repression of the Runx2 Gene in Pre-osteoblasts to Overcome Differentiation...
  Juraj Adamik, Rebecca Silbermann, Silvia Marino, Quanhong Sun, Judith L. Anderson, Dan Zhou, Xiang-Qun Xie, G. David Roodman, Deborah L. Galson> ;Frontiers in Endocrinology. 2018 Jun 29
• 14 citations
  A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America
  Noopur Raje, Garson David Roodman, Wolfgang Willenbacher, Kazuyuki Shimizu, Ramón García-Sanz, Evangelos Terpos, Lisa Kennedy, Lorenzo Sabatelli, M. Intorcia, Guy Hech...> ;Journal of Medical Economics. 2018 Mar 5
• 251 citations
  Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, p...
  Noopur Raje, Evangelos Terpos, Wolfgang Willenbacher, Kazuyuki Shimizu, Ramón García-Sanz, Brian G.M. Durie, Wojciech Legiec, Marta Krejčí, Kamel Laribi, Li Zhu, Paul ...> ;The Lancet. Oncology. 2018 Mar 1
• 67 citations
  Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update
  Kenneth C. Anderson, Nofisat Ismaila, Patrick J. Flynn, Susan Halabi, Sundar Jagannath, Mohammed S. Ogaily, Jim Omel, Noopur Raje, G. David Roodman, Gary C. Yee, Rober...> ;Journal of Clinical Oncology. 2018 Jan 17
• 136 citations
  Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ...
  Peyman Hadji, Matti S. Aapro, Jean-Jacques Body, Michael Gnant, Maria-Luisa Brandi, Jean-Yves Reginster, M. Carola Zillikens, Claus C. Glüer, Tobie de Villiers, Rod Ba...> ;Journal of Bone Oncology. 2017 Jun 1
• 24 citations
  NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma
  Mu Hao, Reinaldo Franqui-Machin, Hongwei Xu, John D. Shaughnessy, Barthel Barlogie, David Roodman, Dawn E. Quelle, Siegfried Janz, Michael H. Tomasson, Ralph D. Sander...> ;Leukemia. 2017 Apr 12
• 53 citations
  EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma-Induced Epigenetic Suppression of Osteoblast Differentiation
  Juraj Adamik, Shunqian Jin, Quanhong Sun, Peng Zhang, Kurt R. Weiss, Judith L. Anderson, Rebecca Silbermann, G. David Roodman, Deborah L. Galson> ;Molecular Cancer Research. 2017 Apr 1
• 57 citations
  Bone Pain Induced by Multiple Myeloma Is Reduced by Targeting V-ATPase and ASIC3.
  Masahiro Hiasa, Tatsuo Okui, Yohance M. Allette, Matthew S. Ripsch, Ge-Hong Sun-Wada, Hiroki Wakabayashi, G. David Roodman, Fletcher A. White, Toshiyuki Yoneda> ;Cancer Research. 2017 Mar 15
• Join now to see all

Journal Articles

• New Drugs and Novel Mechanisms of Action in Multiple Myeloma in 2013: A Report from the International Myeloma Working Group (IMWG)  
  Ocio E, Richardson P, Rajkumar S, Palumbo A, Mateos M, Orlowski R, Kumar S, Usmani S, Roodman GD, Niesvizky R, Einsele H, Anderson K, Dimopoulos M, Avet-Loiseau H, Mel..., Leukemia, 1/1/2013
• Autophagy promotes T cell survival through degradation of proteins of the cell death machinery  
  Kovacs JR, Li C, Yang Q, Li G, Garcia IG, Ju S, Roodman GD, Windle JJ, Zhang X, Lu B, Cell Death Differ, 1/1/2012
• Challenging the current approaches to multiple myeloma- and other cancer related bone diseases: from bisphosphonates to targeted therapy  
  Kleber M, Udi J, Metzke B, Terpos E, Roodman GD, Morgan G, Dispenzieri A, Einsele H, Wasch R, Engelhardt M, Leuk Lymphoma, 1/1/2012
• Maintaining bone health in patients with cancer Highlights of the 7th Annual Community Oncology Conference  
  Roodman GD, Commun Oncol, 1/1/2012
• Vitamin E: good for the heart, bad for the bones?  
  Roodman GD, Nature Medicine, 1/1/2012
• Mechanisms of Bone Metastasis  
  Roodman GD, UpToDate in Oncology On-Line, 1/1/2011
• The use of biochemical markers on bone remodeling in multiple myeloma: a report of the International Myeloma Working Group Review  
  Terpos E, Dimopoulos MA, Sezer O, Roodman GD, Abildgaard N, Vescio R, Tosi P, Garcia-Sanz R, Davies F, Chanan-Khan A, Palumbo A, Sonneveld P, Drake MT, Harousseau JL, ..., Leukemia, 1/1/2010
• Activating transcription factor 4 regulates osteoclast differentiation in mice  
  Cao H, Yu S, Yao Z, Galson DL, Jiang Y, Zhang X, Fan J, Lu B, Guan Y, Luo M, Lai Y, Zhu Y, Kurihara N, Patrene K, Roodman GD, Xiao G, J Clin Invest, 1/1/2010
• Therapeutic options in multiple myeloma: Focus on bortezomib  
  Roodman GD, Clinical Medicine: Therapeutics, 1/1/2009
• Critical role of activating transcription factor 4 in an anabolic action of parathyroid hormone in bone  
  Yu S, Franceshi RT, Luo M, Fan J, Jiang D, Cao H, Kwon TG, Lai Y, Zhang J, Ptrene K, Hankenson K, Roodman GD, Xiao G, PLoS One, 1/1/2009
• Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment  
  Huston A, Leleu X, Jia X, Moreau AS, Ngo HT, Runnels J, Anderson J, Alsayed Y, Roccaro A, Vallet S, Hatjiharissi E, Tai YT, Sportelli P, Munshi N, Richardson P, Hidesh..., Clin Cancer Res, 1/1/2008
• Mechanisms of bone metastasis, pathophysiology of osteonecrosis of the jaw, and integrins, platelets and bone metastasis Meeting Report from Skeletal Complications of...  
  Roodman GD, IBMS BoneKEy, 1/1/2008
• Advancing treatment for metastatic bone cancer: Consensus recommendations from the Second Cambridge Conference Review  
  Coleman RE, Guise TA, Lipton A, Roodman GD, Berenson JR, Body J-J, Boyce BF, Calvi LM, Hadji P, McCloskey EV, Saad F, Smith MR, Suva LJ, Taichman RS, Vessella RL, Weil..., Clin Cancer Res, 1/1/2008
• Targeting Akt and HSP90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment  
  Huston A, Leleu X, Jia X, Moreau A-S, Ngo HT, Runnels J, Anderson J, Alsayed Y, Roccaro A, Vallet S, Hatjiharissi E,, Tai Y-T, Sportelli P, Munshi N, Richardson P, Hid..., Clin Cancer Res, 1/1/2008
• Meeting Reports: Mechanisms of bone metastasis, pathophysiology of osteonecrosis of the jaw, and integrins, platelets and bone metastasis Meeting Report from Skeletal ...  
  Roodman GD, IBMS BoneKEy, 1/1/2008
• Annexin II/Annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer  
  Shiozawa Y, Havens AM, Jung Y, Ziegler AM, Pedersen EA, Wang J, Lu G, Roodman GD, Loberg RD, Pienta KJ, Taichman RS, J Cell Biochem, 1/1/2008
• The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement  
  Hussein MA, Vrionis FD, Allison R, Berenson J, Berven S, Erdem E, Giralt S, Jagannath S, Kyle RA, LeGrand S, Pfugmacher R, Raje N, Rajkumar SV, Randall L, Roodman GD, ..., Leukemia, 1/1/2008
• American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma  
  Kyle RA, Yee GC, Somerfield M, Flynn PJ, Halabi S, Jagannath S, Orlowski RZ, Roodman GD, Twilde P, Anderson K, J Clinical Onc, 1/1/2007
• Eosinophil chemotactic factor-L (ECF-L) enhances osteoclast formation by increasing in osteoclast precursors expression of LFA-1 and ICAM-1  
  Garcia-Palacios V, Chung HY, Choi SJ, Sarmasik A, Kurihara N, Lee JW, Galson DL, Collins R, Roodman GD, Bone, 1/1/2007
• Thalidomide derivative CC-4047 inhibits osteoclast formation by down regulation of PU1  
  Anderson G, Gries M, Kurihara N, Tadashi H, Anderson J, Donnenberg V, Donnenberg A, Ghobrial I, Mapara MY, Stirling D, Roodman GD, Lentzsh S, Blood, 1/1/2006
• MIP-1alpha (CCL3) is Downstream Target of FGFR3 and RAS/MAPK Signaling in Multiple Myeloma  
  Masih-Khan E, Trudel S, Heise C, Li Z, Nadeem V, Wei E, Paterson J, Roodman GD, Claudio JO, Bergsagel PL, Stewart AK, Blood, 1/1/2006
• Textbook of bone metastasis Review  
  Roodman GD, N Engl J Med, 1/1/2006
• IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma  
  Ehrlich LA, Chung HY, Ghobrial I, Choi SJ, Morandi F, Colla S, Rizzoli V, Roodman GD, Giuliani N, Blood, 1/1/2005
• Straties for maintaining bone health in your oncology patient: A case-based approach  
  Roodman GD, Bone Metastasis Newletter, 1/1/2005
• Legumain expression in relation to clinicopathologic and biological varibles in colorectal cancer  
  Murthy RV, Arbman G,Gao J, Roodman GD, Sun XF, Clin Cancer Res, 1/1/2005
• Join now to see all

Books/Book Chapters

• Volume 21 – Cancer Metastasis – Biology and Treatment 
  Chapter: Pathophysiology of Bone Metastases: Bone Metastases: A Translational and Clinical Approach. 
  Chirgwin JM, Roodman GDEditors: Vassiliou V, Chow E, and Kardamakis D.SpringerEdition 2,2014
• Genetic and Molecular Epidemiology of Multiple Myeloma 
  Chapter: Role of Bone Disease in the Pathogenesis of Multiple Myeloma. 
  Roodman GDEditors: Suzanne Lentzsch.Springer, New York, NY2013
• In Bone Metabolic Functions and Modulators (topics in Bone Biology Series Vol 7) 
  Chapter: Paget’s disease of bone: Pathogenesis and treatment. 
  Singer F and Roodman GDEditors: F. Bronner and M. Farach-Carson.2012
• Cecil Textbook of Medicine. 
  Chapter: Paget’s Disease of Bone. Chapter 225 
  Page 1603 - 1605Roodman GDEditors: L Goldman and A.I. Schafer.Elsevier, Philadelphia, PAEdition 24,2011
• Bortezomib in the Treatment of Multiple Myeloma. 
  Chapter: Bortezomib and osteoclast and osteoblasts. 
  Page 43 - 52Krauze MT, Roodman GDEditors: Anderson KC, Richards P.G., Ghobrial I.Springer, New York, NY2011
• ASCO Educational Book 2010. 
  Chapter: Emerging treatments for myeloma bone disease. 
  Roodman GDAlexandria, VA2010
• Handbook of Cancer-Related Bone Disease. 
  Chapter: Bone Health in Myeloma. Chapter 8. 
  Page 133 - 143Roodman GDEditors: Coleman RE, Abrahamsson P-A, Hadji P.BioScientifica, Bristol, United Kingdom2010
• Advances in Bone Cancer Treatment: Preventing Metastasis and Bone Loss (monograph). 
  Chapter: Pathophysiology of Bone Metastasis. 
  Page 6 - 8Roodman GDInforMEDical Communications, Inc., Carlisle, MA2010
• Osteoimmunology 
  Chapter: Origins of Osteoclasts. 
  Page 7 - 41Galson DL and Roodman GDEditors: J Lorenzo, Y Choi, M Horowitz, and H Takayanagi.Academic Press, New York, NY2010
• Bone and Cancer, Topics in Bone Biology. Vol 5. 
  Chapter: Multiple Myeloma and Other Hematological Malignancies of Bone. Chapter 3. 
  Page 43 - 55Sehgal R, Sanfilippo K, Roodman GDEditors: F. Bronner, M.C. Farach-Carson.Springer, London, United Kingdom2009
• Skeletal Imaging and Management of Bone Disease. 
  Roodman GD2008
• Primer on Metabolic Bone Disease and Disorders of Mineral Metabolism 
  Chapter: Hematologic Malignancies and Bone. Chapter 80. 
  Page 379 - 382McHayleh WM, Ellerman J, Roodman GDEditors: D Welk.The American Society for Bone and Mineral Research, Washington, DCEdition 7,2008
• Primer on Metabolic Bone Disease and Disorders of Mineral Metabolism 
  Chapter: Paget's Disease of Bone. Chapter 72. 
  Page 335 - 343Siris ES, Roodman GDEditors: D Welk.The American Society for Bone and Mineral Research, Washington, DCEdition 7,2008
• Bone Metastases: A Translational and Clinical Approach. 
  Chapter: Pathophysiology of Bone Metastasis. Chapter 2 
  Page 31 - 50Roodman GDEditors: Kardamakis, Vissiliou, Chow.Springer, Heidelberg, Germany2008
• Treatment of Multiple Myeloma and Related Disorders. 
  Chapter: Diagnosis and Treatment of myeloma bone disease. Chapter 6 
  Page 64 - 75Roodman GDEditors: SV Rajkumar and RA Kyle.Cambridge University Press, New York, NY2008
• Cancer Metastasis Textbook. 
  Chapter: Bone Complications of Myeloma and Lymphoma. 
  Roodman GDCambridge University Press2008
• Translational Therapeutic Strategies in Multiple Myeloma. 
  Chapter: Myeloma Bone Disease. Chapter 3. 
  Page 45 - 60Huston A, Roodman GDEditors: I.M. Ghobrial and K.A. Anderson.Informa Healthcare, New York, NY2007
• Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 
  Chapter: Paget's Disease of Bone. Chapter 59. 
  Page 320 - 330Siris ES, Roodman GDEditors: M Favus.The American Society for Bone and Mineral Research, Washington, DCEdition 6,2005
• Cecil Textbook of Medicine. 
  Chapter: Paget's Disease of Bone. 
  Roodman GDEditors: D Clemmons.WB Saunders, Philadelphia, PAEdition 22,2005
• Cecil Textbook of Medicine 
  Chapter: Chapter 76. Paget's disease of bone. 
  Horwitz MJ, Roodman GD2005
• Cecil Essentials of Medicine. 
  Chapter: Paget’s Disease of Bone. 
  Page 723 - 727Horwitz MJ, Roodman GDEditors: TE Andreoli.WB Saunders, Philadelphia, PAEdition 6,2004
• The Skeleton: Biochemical Genetic, and Molecular Interactions in Development and Homeostasis. 
  Chapter: Osteoclast Differentiation. 
  Page 195 - 214Reddy SV, Roodman GDEditors: EJ Massaro, JR Rogers.Humana Press, Inc.2004
• Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 
  Chapter: Paget's Disease of Bone. 
  Page 495 - 506Siris ES, Roodman GDEditors: M Favus.The American Society for Bone and Mineral Research, Washington, DCEdition 5,2003
• ASH Education Program Book, Hematology. 
  Chapter: Multiple Myeloma. 
  Page 214 - 240Anderson KC, Shaughnessy JD, Barlogie B, Harousseau J-L, Roodman GDEditors: J Bajus.2002
• Reviews in Endocrine & Metabolic Disorders. 
  Chapter: Paget's Disease of Bone: A Disease of the Osteoclast. 
  Page 195 - 201Reddy SV, Kurihara N, Menaa C, Roodman GDEditors: N Bell, S Epstein, E Canalis.Kluwer Academic Publishers, Norwell, MA2001
• Join now to see all

Abstracts/Posters

• Development of a Novel Deep Transfer Learning Framework to Characterize Inter- and Intra-Tumor Heterogeneity in Myeloma Patients
  G. David Roodman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Pivotal Role of OCL-Derived IGF1 in Drug Resistance and Bone Destruction in MM
  G David Roodman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Antioxidant therapy ameliorates ionizing irradiation induced delay in bone fracture healing.
  Gokhale AS, Epperly M, Glowacki J, Smith T, Patrene K, Roodman GD, Greenberger JS, AACR 100th Annual Meeting, Denver, CO, 1/1/2009
• Expression of Increased Levels of TAFII-17 Combined with IL-6 in Normal OCL Precursors Induce Formation of Osteoclasts (OCLs) that Express a Pagetic Phenotype.
  Hiruma Y, Windle JJ, Roodman GD, Kurihara N, American Society of Bone and Mineral Research, Denver, CO, 1/1/2009
• ADAM8 Enhances Osteoclast (OCL) Precursor Number and Increases OCL Activity In Vitro.
  Ishizuka H, Kurihara K, Windle JJ, Roodman GD, American Society of Bone and Mineral Research, Denver, CO, 1/1/2009
• Stabilization of 1,25-(OH)2D3-VDR Complex by VDR Coactivator TAFII-17 in Pagetic Osteoclast Precursor Cells.
  Ishizuka S, Kurihara N, Roodman GD, American Society of Bone and Mineral Research, Denver, CO, 1/1/2009
• Treatment of Osteoclast (OCL) Precursors Expressing the Measles Virus Nucleocapsid Protein (MVNP) with 1,25-(OH)2D3 Increases Expression of Specific AP-1 Subtypes.
  Kurihara N, Windle JJ, Roodman GD, American Society of Bone and Mineral Research, Denver, CO, 1/1/2009
• Cooperation between IL-7 and TNF-alpha Results in Suppression of Runx2/Cbfa1 Expression and Inhibition of Osteoblast Differentiation in Myeloma.
  Del Prete D, Yu S, Xiao G, Roodman GD, American Society of Hematology 50th Annual Meeting, San Francisco, CA, 1/1/2008
• Suppression of Mesenchymal Stromal Cell (MSC) Differentiation in Multiple Myeloma (MM) is Restricted to the Osteoblast Lineage.
  Esteve F, Hong CS, Huston A, Garcia Palacios V, Anderson J, Patrene K, Roodman GD, American Society of Hematology 50th Annual Meeting, San Francisco, CA, 1/1/2008
• Increased signaling through p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formation.
  Yuko Hiruma Y, Noriyoshi Kurihara N, Diane Jelinek D, G.David Roodman GD, American Society of Hematology 50th Annual Meeting, San Francisco, CA, 1/1/2008
• A randomized, phase III trial to evaluate pegylated liposomal doxorubicin added to a regimen of thalidomide and dexamethasone in subjects with newly diagnosed multiple...
  Rifkin R, Roodman GD, Richards D, Leach J, Mohrbacher A, Luo D, Lowery C, ASCO Annual Meeting, Chicago, IL, 1/1/2008
• Angiogenic potential of osteoclasts.
  Cackowski FC, Choksi RJ, Windle JJ, Roodman GD, ASBMR 30th Annual Meeting, Montreal, Canada, 1/1/2008
• Role of Annexin II and Annexin II Receptor in Homing Multiple Myeloma Cells in the Bone Marrow.
  Del Prete D, Lu G, Esteve F, Shiozawa Y, Taichman RS, Roodman GD, ASBMR 30th Annual Meeting, Montreal, Canada, 1/1/2008
• The Rapid-Nontranscriptional Action of 1,25 (OH)2D3 Induces IL-6 Production in Osteoclast Precursors Expressing Measles Virus Nucleocapsid Protein (MVNP).
  Hiruma Y, Ishizuka S, Roodman GD, Kurihara N, ASBMR 30th Annual Meeting, Montreal, Canada, 1/1/2008
• Increased Signaling through p62 in the Multiple Myeloma Microenvironment Increases Myeloma (MM) Cell Growth and Osteoclast (OCL) Formation.
  Hiruma Y, Kurihara N, Roodman GD, ASBMR 30th Annual Meeting, Montreal, Canada, 1/1/2008
• Co-Expression of p62P392L and MVNP in Osteoclasts (OCL) Precursors Increases the Formation of OCL that Express a Pagetic Phenotype
  Hiruma Y, Kurihara N, Zhou H, Subler MA, Dempster DW, Windle JJ, Roodman GD, ASBMR 30th Annual Meeting, Montreal, Canada, 1/1/2008
• High Levels of IL-6 and Hyper-responsivity to 1,25-(OH)2D3 Are Both Required for Development of Pagetic Osteoclasts (PD-OCL).
  Hiruma Y, Kurihara N, Zhou H, Subler MA, Dempster DW, Windle JJ, Roodman GD, ASBMR 30th Annual Meeting, Montreal, Canada, 1/1/2008
• 1,25-dihydroxyvitamin D3 Can Directly Induce Osteoclast Formation in Osteoclast Precursors in the Absence of RANKL.
  Kurihara N, Hiruma Y, Lorenzo JA, Roodman GD, ASBMR 30th Annual Meeting, Montreal, Canada, 1/1/2008
• High Dose of RANKL Rescues Integrin alpha9-/- Osteoclast Phenotype.
  Lu G, Hiruma Y, Boykin CK, Patrene K, Anderson J, Del Prete D, Windle JJ, Roodman GD, ASBMR 30th Annual Meeting, Montreal, Canada, 1/1/2008
• Pathogenesis of Lung Cancer Bone Metastasis.
  Roodman GD, IASLC 12th World Conference on Lung Cancer, Seoul, Korea, 1/1/2007
• Experimental Studies in Paget’s Disease.
  Roodman GD, Molecular Pharmacology & Paget’s Disease Meetings, St. Catherine’s College, Oxford, United Kingdom, 1/1/2007
• Changes in VDR Coregulator Recruitment Result in 1alpha,25(OH)2D3 Hypersensitivity in (MVNP) Expressing Cells.
  Hidalgo A, Florea J, Roodman GD, Kurihara N, Onate S, ASBMR 29th Annual Meeting, Honolulu, HI, 1/1/2007
• Mutations in p62 Linked to Paget's Disease Makes the Bone Microenvironment Highly Osteoclastogenic.
  Hiruma Y, Kurihara N, Subler MA, Zhou H, Dempster DW, Ishizuka S, Roodman GD, Windle JJ, ASBMR 29th Annual Meeting, Honolulu, HI, 1/1/2007
• Measles Virus Nucleocapsid Gene Expression is Required for Abnormal Osteoclast Activity in Paget’s Disease of Bone.
  Kurihara N, Hiruma Y, Yamana K, Rousseau C, Morissette J, Brown JP, Roodman GD, ASBMR 29th Annual Meeting, Honolulu, HI, 1/1/2007
• Clinical Applications of the RANK/RANKL OPG Pathway in Cancer Induced Bone Loss.
  Roodman GD, ASBMR 29th Annual Meeting, Honolulu, HI, 1/1/2007
• Join now to see all

Lectures

• Optimal Use of Bisphosphonates and Other Agents in Bone Disease in Multiple Myeloma 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
• Multidisciplinary Perspective on Best Practices in Multiple Myeloma. Invited Speaker 
  Saginaw, MI - 1/1/2013
• Paget’s Disease – Virus or Gene. Invited Speaker 
  Seoul, Korea - 1/1/2013
• Targeting the Microenvironment in myeloma. Invited Speaker 
  Seoul, Korea - 1/1/2013
• Novel targets for myeloma bone disease. Keynote Speaker 
  Sydney, Australia - 1/1/2013
• The Future of Diagnosis and Treatment of Metastatic Bone Disease. Invited Panelist 
  Sydney, Australia - 1/1/2013
• Contribution of the Marrow Microenvironment To Chemoresistance in Myeloma. Invited Speaker 
  1/1/2013
• Multidisciplinary Care of Veterans With Myeloma. Invited Speaker 
  VA Medical Center, Pittsburgh, PA - 1/1/2013
• Supportive Care Options. Invited Speaker 
  Chicago, IL - 1/1/2013
• Paget’s Disease: Virus, Gene or Both? Invited Speaker 
  Bethesda, MD - 1/1/2012
• Optimal Treatment of Multiple Myeloma in the Frontline and Relapse/Refractory Settings. Invited Speaker 
  Biloxi, MI - 1/1/2012
• The role of bone cells in tumor growth progression in myeloma. Invited Speaker 
  Corfu, Greece - 1/1/2012
• The Role Myeloma Bone Disease. Invited Speaker 
  Hackensack, NJ - 1/1/2012
• Patient Survivor Care: Maintaining Bone Health. Invited Speaker 
  Las Vegas, NV - 1/1/2012
• Multiple Myeloma Bone Disease. Invited Speaker 
  New York, NY - 1/1/2012
• Powerful Thinking Advances for Cure. Invited Speaker 
  Old Greenwich, CT - 1/1/2012
• Update on Paget’s Disease. Invited Speaker 
  Oxford, United Kingdom - 1/1/2012
• Genetic bone disease: Paget’s disease of the bone. Invited Speaker 
  Oxford, United Kingdom - 1/1/2012
• Bone-Targeting Therapies in Multiple Myeloma: Improving Patient Outcomes Extending Survival. Invited Speaker 
  Silver Springs, MD - 1/1/2011
• Pathogenetic mechanisms of myeloma-associated bone disease. Invited Speaker 
  University of Bari, Italy - 1/1/2011
• Paget’s Disease 
  University of Pittsburgh - 1/1/2011
• Monoclonal Gammopahy 
  UPMC Cancer Center - 1/1/2011
• Bone-Targeting Therapies in Multiple Myeloma: Improving Patient Outcomes, Extending Survival. Invited Speaker 
  Virginia Beach, VA - 1/1/2011
• Paget's Disease – Virus, gene or Both. Invited Speaker 
  Bethesda, MD - 1/1/2011
• What can we do to Improve Bone Health of Patients with Multiple Myeloma. Invited Speaker 
  Chicago, IL - 1/1/2011
• Join now to see all

Other

• Advances in treating metastatic bone cancer. Monograph. 
  Roodman GD, et al
  1/1/2008
• Treating Agent for Paget's Disease of Bone 
  Roodman GD, U.S. Patent (7,163,933 B2)
  1/16/2007
• Method of Resisting Osteoclast Formation 
  Roodman GD, U.S. Patent (10/650,277)
  1/28/2003
• Compositions and Methods of Use for Osteoclast Inhibitory Factors 
  Roodman GD, U.S. Patent #5,985,832
  1/16/1999
• Chemokine Inhibiting Peperazine Derivatives and Their Use to Treat Multiple Myeloma 
  Roodman GD, U.S. Patent (11/051,522)
• Join now to see all